Labour market · 22/10/20261 min read
Georgiamune and the Menarini Group conclude an exclusive global licensing and collaboration agreement on GIM-621, an innovative oral immuno-oncological agent
Summary
GIM-621 is an innovative, preclinical, small molecule oral immunotherapy that has potential for application in the treatment of several solid tumours.